Alfacell Corporation says that new findings for the treatment of unresectable malignant mesothelioma were presented on Sunday, October 22 at the 8th International Conference of the International Mesothelioma Interest Group.  The post-hoc analysis found that patients treated with Onconase had greater median survival times than patients treated with doxorubicin alone.
Alfacell Corporation says that new findings […]

Simple Blood Test will help doctors monitor patients with biphasic and epithelioid mesothelioma The Food and Drug Administration (FDA) on January 25, 2007 approved the MESOMARK(R) Assay, the world’s first in-vitro test for mesothelioma, a rare and aggressive form of cancer caused by asbestos exposure.  MESOMARK will allow doctors to monitor patients with epithelioid and […]